Clinical Trial Update: Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine [Phase 2]

View source ↗

Summary

Phase 2 trial comparing cardiovascular side effects of Teysuno versus capecitabine in gastrointestinal cancers completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Neoplasms
• Cancer of Unknown Primary Site
• Gastrointestinal Cancer
• Pancreatic Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Teysuno (tegafur; gimeracil; oteracil)

Snippet

Sponsor: University of Edinburgh | Conditions: Gastrointestinal Cancer, Cancer of Unknown Primary Site | Phase 2 | Status: COMPLETED